JP2021523101A - 切断可能なｃ末端電荷対タグを有する二重特異性抗体 - Google Patents

切断可能なｃ末端電荷対タグを有する二重特異性抗体 Download PDF

Info

Publication number
JP2021523101A
JP2021523101A JP2020560761A JP2020560761A JP2021523101A JP 2021523101 A JP2021523101 A JP 2021523101A JP 2020560761 A JP2020560761 A JP 2020560761A JP 2020560761 A JP2020560761 A JP 2020560761A JP 2021523101 A JP2021523101 A JP 2021523101A
Authority
JP
Japan
Prior art keywords
amino acid
domain
polypeptide
tag
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020560761A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523101A5 (https=
JPWO2019217587A5 (https=
Inventor
カウォーヤ，ジョン・ケイ
ジョコビッツ，アレックス・タブリュ
モール，クリフトファー
スミス，スティーブン
グラハム，ケビン
ロウ，レイ・リエ・ユン
ティール，オリバー
ロマニーニ，ダンテ
ワグナー，ビクトリア
アグラワル，ニーラジ・ジェイ
Original Assignee
アムジエン・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アムジエン・インコーポレーテツド filed Critical アムジエン・インコーポレーテツド
Publication of JP2021523101A publication Critical patent/JP2021523101A/ja
Publication of JP2021523101A5 publication Critical patent/JP2021523101A5/ja
Publication of JPWO2019217587A5 publication Critical patent/JPWO2019217587A5/ja
Priority to JP2023191593A priority Critical patent/JP7785734B2/ja
Priority to JP2025219116A priority patent/JP2026035775A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2020560761A 2018-05-08 2019-05-08 切断可能なｃ末端電荷対タグを有する二重特異性抗体 Pending JP2021523101A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023191593A JP7785734B2 (ja) 2018-05-08 2023-11-09 切断可能なｃ末端電荷対タグを有する二重特異性抗体
JP2025219116A JP2026035775A (ja) 2018-05-08 2025-12-02 切断可能なｃ末端電荷対タグを有する二重特異性抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862668626P 2018-05-08 2018-05-08
US62/668,626 2018-05-08
PCT/US2019/031379 WO2019217587A1 (en) 2018-05-08 2019-05-08 Bispecific antibodies with cleavable c-terminal charge-paired tags

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023191593A Division JP7785734B2 (ja) 2018-05-08 2023-11-09 切断可能なｃ末端電荷対タグを有する二重特異性抗体

Publications (3)

Publication Number Publication Date
JP2021523101A true JP2021523101A (ja) 2021-09-02
JP2021523101A5 JP2021523101A5 (https=) 2022-05-16
JPWO2019217587A5 JPWO2019217587A5 (https=) 2022-05-16

Family

ID=66676901

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020560761A Pending JP2021523101A (ja) 2018-05-08 2019-05-08 切断可能なｃ末端電荷対タグを有する二重特異性抗体
JP2023191593A Active JP7785734B2 (ja) 2018-05-08 2023-11-09 切断可能なｃ末端電荷対タグを有する二重特異性抗体
JP2025219116A Pending JP2026035775A (ja) 2018-05-08 2025-12-02 切断可能なｃ末端電荷対タグを有する二重特異性抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023191593A Active JP7785734B2 (ja) 2018-05-08 2023-11-09 切断可能なｃ末端電荷対タグを有する二重特異性抗体
JP2025219116A Pending JP2026035775A (ja) 2018-05-08 2025-12-02 切断可能なｃ末端電荷対タグを有する二重特異性抗体

Country Status (8)

Country Link
US (2) US12384849B2 (https=)
EP (1) EP3790904A1 (https=)
JP (3) JP2021523101A (https=)
AU (2) AU2019265699B2 (https=)
CA (1) CA3099450A1 (https=)
MA (1) MA52571A (https=)
MX (2) MX2020011844A (https=)
WO (1) WO2019217587A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020304671A1 (en) * 2019-06-28 2022-01-20 Amgen Inc. Anti-CGRP receptor/anti-PAC1 receptor bispecific antigen binding proteins
EP4466020A4 (en) * 2022-01-21 2026-04-15 Lyvgen Biopharma Holdings Ltd Multi-specific antibodies and their uses in avidity receptor cross-linking and immune modulation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013505238A (ja) * 2009-09-16 2013-02-14 ジェネンテック， インコーポレイテッド コイルドコイルおよび／またはテザー含有タンパク質複合体およびその使用
WO2017034770A1 (en) * 2015-08-26 2017-03-02 Bison Therapeutics Inc. Multispecific antibody platform and related methods

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
US7101692B2 (en) * 1999-04-15 2006-09-05 The Regents Of The University Of California Identification of sortase gene
WO2001000814A2 (en) * 1999-06-25 2001-01-04 Universität Zürich Hetero-associating coiled-coil peptides and screenign method therefor
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
US20050214300A1 (en) * 2002-11-25 2005-09-29 Chiron Corporation Methods for treating cancer using Porimin as a target
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
EP2824111B1 (en) * 2010-04-30 2017-03-22 Alexion Pharmaceuticals, Inc. Anti-C5A Antibodies and Methods for Using the Antibodies
US10851178B2 (en) * 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
JO3519B1 (ar) * 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
SG11201508732PA (en) * 2013-04-25 2015-11-27 Scripps Korea Antibody Inst Method for refining protein including self-cutting cassette and use thereof
RS61907B1 (sr) 2015-04-06 2021-06-30 Subdomain Llc Polipeptidi koji sadrže de novo vezujući domen i njihova primena

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013505238A (ja) * 2009-09-16 2013-02-14 ジェネンテック， インコーポレイテッド コイルドコイルおよび／またはテザー含有タンパク質複合体およびその使用
WO2017034770A1 (en) * 2015-08-26 2017-03-02 Bison Therapeutics Inc. Multispecific antibody platform and related methods

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BEERLI R R; ET AL: "SORTASE ENZYME-MEDIATED GENERATION OF SITE-SPECIFICALLY CONJUGATED ANTIBODY DRUG 以下備考", PLOS ONE, vol. VOL:10, NR:7,, JPN5021009237, July 2015 (2015-07-01), US, pages 0131177 - 1, ISSN: 0005052422 *
KOEN WAGNER; ET AL: "BISPECIFIC ANTIBODY GENERATED WITH SORTASE AND CLICK CHEMISTRY HAS BROAD 以下備考", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. VOL:111, NR:47,, JPN5021009238, 10 November 2014 (2014-11-10), pages 16820 - 16825, ISSN: 0005052421 *
WRANIK B J; ET AL: "LUZ-Y, A NOVEL PLATFORM FOR THE MAMMALIAN CELL PRODUCTION OF FULL-LENGTH IGG-BISPECIFIC ANTIBODIES", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. VOL:287, NR:52,, JPN5021009236, November 2012 (2012-11-01), pages 43331 - 43339, ISSN: 0005052423 *

Also Published As

Publication number Publication date
JP2024023264A (ja) 2024-02-21
AU2019265699A1 (en) 2021-01-07
MX2020011844A (es) 2021-04-13
US20220089756A1 (en) 2022-03-24
AU2019265699B2 (en) 2026-03-12
EP3790904A1 (en) 2021-03-17
JP7785734B2 (ja) 2025-12-15
AU2026201242A1 (en) 2026-04-23
CA3099450A1 (en) 2019-11-14
MX2025001939A (es) 2025-04-02
US12384849B2 (en) 2025-08-12
MA52571A (fr) 2021-03-17
US20250197518A1 (en) 2025-06-19
WO2019217587A1 (en) 2019-11-14
JP2026035775A (ja) 2026-03-04

Similar Documents

Publication Publication Date Title
JP7250863B2 (ja) カッパ及びラムダ軽鎖を含む抗原結合ポリペプチド構築物及びその使用
JP2021019598A (ja) Ｆｃ含有ポリペプチドの安定化
US10982008B2 (en) Domain-exchanged antibody
AU2015252866B2 (en) Compositions and methods related to engineered Fc constructs
KR102590061B1 (ko) 유전자 조작 Fc 작제물에 관한 조성물 및 방법
US20250197518A1 (en) Bispecific antibodies with cleavable c-terminal charge-paired tags
EP3487532A1 (en) Modified antigen-binding fab fragments and antigen-binding molecules comprising the same
CN110234355A (zh) 单体人IgG1 Fc和双特异性抗体
AU2020268684A1 (en) Variant domains for multimerizing proteins and separation thereof
JP2020529986A (ja) Ｃｙｓ−ｍａｂのコンジュゲーション方法
JP7837331B2 (ja) Ｃｌｄｎ６及びｃｄ３に選択的に結合するポリペプチド構築物
CN113439089A (zh) 截短的多价多元体
US20210284717A1 (en) Compositions and methods related to engineered fc-antigen binding domain constructs
JP2020530265A (ja) 安定化したキメラＦａｂ
WO2026056998A1 (zh) Gipr结合分子及医药用途
KR20250067799A (ko) 항-flag 항체
WO2025250941A1 (en) Cμ4 REGION FOR PAIRING HEAVY AND LIGHT CHAINS IN MULTI-SPECIFIC ANTIBODIES
JP2026064000A (ja) 抗原結合分子
TW202438527A (zh) 抗b7h3抗體以及其使用方法
HK40075825A (en) Antigen-binding protein and use thereof
HK40075825B (en) Antigen-binding protein and use thereof
CA3111462A1 (en) Improved anti-flt3 antigen binding proteins

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220506

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220506

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230509

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230803

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240109